Rifaximin vaginal suppository for livestock and preparation method for same

A technology of rifaximin and vaginal suppository, which is applied in the field of rifaximin vaginal suppository for livestock and its preparation, can solve the problems of rifaximin difficulty, influence on antibacterial effect, disintegration time limit and dissolution timeout, etc., and achieve optimal Melting time limit, strong antibacterial effect, overcoming the effect of long melting time limit

Active Publication Date: 2012-06-27
ZHENGZHOU BARY ANIMAL PHARMA
View PDF3 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Rifaximin is insoluble in water. When conventional methods are used to prepare suppositories, the d

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Rifaximin vaginal suppository for livestock and preparation method for same
  • Rifaximin vaginal suppository for livestock and preparation method for same
  • Rifaximin vaginal suppository for livestock and preparation method for same

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] Rifaximin solid dispersion preparation

[0028] prescription:

[0029]

[0030] Weigh PEG1000 and PEG4000 according to the prescription content, melt in a water bath at 70°C-80°C, add rifaximin solution that has been dissolved in 8.0g of absolute ethanol, stir well, evaporate the ethanol in a water bath at 70°C-80°C, and then cool down rapidly Cool and solidify to obtain the solid dispersion of rifaximin.

Embodiment 2

[0032] Rifaximin solid dispersion preparation

[0033] prescription:

[0034]

[0035]Weigh PEG1000 and Poloxamer F68 according to the prescription content, melt in a water bath at 70°C-80°C, add rifaximin solution that has been dissolved in 8.0g of absolute ethanol, stir well, evaporate the ethanol in a water bath at 70°C-80°C Afterwards, the temperature is rapidly lowered and cooled to solidify, and the solid dispersion of rifaximin is obtained.

Embodiment 3

[0037] Rifaximin solid dispersion preparation

[0038] prescription:

[0039]

[0040] Weigh PEG4000 and poloxamer F68 according to the prescription content, melt in a water bath at 70°C-80°C, add rifaximin solution that has been dissolved in 8.0g of absolute ethanol, stir well, evaporate the ethanol in a water bath at 70°C-80°C Afterwards, the temperature is rapidly lowered and cooled to solidify, and the solid dispersion of rifaximin is obtained.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the field of veterinary medicine, and particularly relates to a rifaximin vaginal suppository for livestock and a preparation method for the same. The suppository contains the following components: 8.5-25.5 parts by weight of rifaximin solid dispersion, 30-88 parts by weight of matrix, 6.0-12.5 parts by weight of water, 0.01-1.0 parts by weight of surfactant, 0.01-10.0 parts by weight of synergist and 0.01-5.0 parts by weight of preservative, wherein the rifaximin solid dispersion is obtained by melting 7.3-21.9 parts by weight of solid dispersion carrier in a water bath at 70-80 DEG C, and then adding the used 2-16 parts by weight of absolute ethyl alcohol to dissolve 1.2-3.6 parts by weight of rifaximin to obtain rifaximin solution, uniformly stirring, steaming away the absolute ethyl alcohol in the water bath at 70-80 DEG C, and then rapidly cooling and solidifying. The suppository disclosed by the invention can ensure the uniform dispersion of main medicine and overcome the problems of low heat resistance and long melting time limit of glycerin gelatine matrix.

Description

technical field [0001] The invention belongs to the field of veterinary medicine, and relates to a rifaximin vaginal suppository for livestock and a preparation method thereof. Background technique [0002] Rifaximin (Rifaximin) is a semi-synthetic derivative of rifamycin SV, which is a broad-spectrum, high-efficiency, low-toxic intestinal or topical antibiotic. The drug was developed by the Italian Alpha Company. It was first launched in Italy in 1987 as an anti-infective diarrhea drug, and then widely used in Europe and the United States. In 2004, it was approved by the SFDA for clinical application in my country, mainly for the prevention and treatment of sensitive bacteria. Acute and chronic intestinal infections caused by It has been reported that the marketed dosage forms include dry suspension, capsules, tablets, granules, etc. for oral administration. [0003] Rifaximin has a broad antibacterial spectrum and strong antibacterial activity. For Gram-positive aerobic ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/02A61K31/437A61P15/00A61P31/04
Inventor 余祖功李晶张海彬张军忍江善祥
Owner ZHENGZHOU BARY ANIMAL PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap